Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of precision medicine through artificial intelligence, has announced the acquisition of Paige, a leader in AI-powered digital pathology. The deal, valued at $81.25 million, is primarily structured as an equity transaction in Tempus common stock, with Tempus also assuming Paige’s existing commitment under its Microsoft Azure cloud services agreement. Paige, founded in 2017, has built a strong foundation in pathology and AI by developing one of the most extensive datasets in the field—comprising nearly 7 million digitized, clinically annotated pathology slides. This dataset includes diverse patient information from 45 countries, spanning various genders, races, ethnicities, and geographic regions, all de-identified to ensure privacy. The company has also pioneered the first FDA-cleared AI application in pathology, enabling more accurate cancer detection and supporting better-informed treatment decisions. Paige’s technological achievements include the development of the first million-slide foundation model for cancer, a critical advancement that enhances the ability of researchers and pharmaceutical companies to analyze pathology data and accelerate drug discovery and development. Eric Lefkofsky, Founder and CEO of Tempus, highlighted the strategic value of the acquisition. “As we work toward building the largest foundation model ever created in oncology, the acquisition of Paige dramatically accelerates our progress,” he said. “Paige has established one of the most comprehensive digital pathology datasets in the world, particularly through its collaboration with Memorial Sloan Kettering Cancer Center. Their team’s deep expertise in generative AI, combined with this unique dataset, will be transformative across all of our AI initiatives.” Razik Yousfi, CEO and CTO of Paige, expressed enthusiasm about the partnership. “Our mission has always been to harness AI to revolutionize cancer care by transforming how pathology is used in diagnosis and treatment. Joining forces with Tempus, a company already driving innovation in oncology, allows us to scale our impact and bring life-changing insights to more patients worldwide. We are confident this collaboration will maximize the reach and effectiveness of our technology.” The acquisition strengthens Tempus’ position in precision medicine by expanding its multimodal data library and adding a highly skilled technical team with proven experience in AI and digital pathology. With access to Paige’s vast, diverse dataset and advanced AI tools, Tempus aims to enhance its existing diagnostic platforms and accelerate the development of next-generation AI models for cancer care. Tempus continues to advance its mission of delivering personalized, data-driven healthcare solutions by leveraging AI to learn from the collective experience of patients, ultimately improving outcomes for individuals through insights derived from large-scale, real-world data. The transaction is subject to customary closing conditions, and both companies expect the integration to proceed smoothly, with Paige’s technology and team becoming fully embedded within Tempus’ operations.